Petra Financial Advisors Inc. Takes Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Petra Financial Advisors Inc. purchased a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 398 shares of the medical equipment provider’s stock, valued at approximately $208,000.

Other large investors have also made changes to their positions in the company. M.E. Allison & CO. Inc. acquired a new stake in shares of Intuitive Surgical during the fourth quarter valued at $449,000. Seilern Investment Management Ltd acquired a new stake in shares of Intuitive Surgical during the fourth quarter valued at $82,517,000. Sycomore Asset Management boosted its stake in shares of Intuitive Surgical by 27.4% during the fourth quarter. Sycomore Asset Management now owns 18,945 shares of the medical equipment provider’s stock valued at $9,214,000 after acquiring an additional 4,079 shares during the last quarter. Exome Asset Management LLC boosted its stake in shares of Intuitive Surgical by 16.8% during the third quarter. Exome Asset Management LLC now owns 7,427 shares of the medical equipment provider’s stock valued at $3,649,000 after acquiring an additional 1,069 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Intuitive Surgical by 5.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,843 shares of the medical equipment provider’s stock valued at $5,138,000 after acquiring an additional 525 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG opened at $488.80 on Tuesday. Intuitive Surgical, Inc. has a one year low of $364.17 and a one year high of $616.00. The company has a market cap of $174.10 billion, a PE ratio of 76.26, a P/E/G ratio of 5.85 and a beta of 1.43. The stock has a 50-day moving average of $566.38 and a 200-day moving average of $531.96.

Insiders Place Their Bets

In other news, Director Amal M. Johnson sold 4,635 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the completion of the sale, the director now owns 12,275 shares in the company, valued at $6,955,015. This trade represents a 27.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Jamie Samath sold 269 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $590.00, for a total transaction of $158,710.00. Following the sale, the chief financial officer now owns 3,282 shares of the company’s stock, valued at approximately $1,936,380. The trade was a 7.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,754 shares of company stock valued at $17,691,621 in the last 90 days. 0.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently commented on the company. Citigroup increased their price objective on Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Royal Bank of Canada increased their price objective on Intuitive Surgical from $611.00 to $641.00 in a research note on Monday, January 27th. BTIG Research raised their price target on Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Morgan Stanley raised Intuitive Surgical from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $522.00 to $650.00 in a research note on Monday, December 2nd. Finally, Barclays raised their price target on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $610.19.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.